Hematologic Malignancy
Adult Acute Myeloid Leukemia
CI-CAN-00004346Explore in graph →
Hematologic64 active trials
- NCIt
- C9154
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00004346Explore in graph →
Clinical trials
374 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (72)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07478991 | Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)(VENP-A-QUI) | recruiting | Phase 3 | 376 | PETHEMA FoundationOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06652438 | Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML | recruiting | Phase 3 | 448 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 18 | Sep 2, 2026 |
| clinicaltrials |
| NCT05429632 | Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT(MO-TRANS) | recruiting | Phase 3 | 366 | Priothera SASINDUSTRY | 14 | Jul 17, 2026 | clinicaltrials |
| NCT07407140 | VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML(VAG-3+7-G) | not yet recruiting | Phase 3 | 300 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Mar 25, 2026 | clinicaltrials |
| NCT07132684 | Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients | recruiting | Phase 3 | 240 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05674539 | Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome | enrolling by invitation | Phase 3 | 200 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT05177731 | Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML | active not recruiting | Phase 3 | 188 | Chen SuningOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT06297772 | Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR | not yet recruiting | Phase 3 | 220 | Ruijin HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
Data updated 19 hours agoSource updated Sep 29, 2026source: clinicaltrials